Stockscreener 앱 받기
3.37
0.59%
-0.02
시장 영업 전:
4.28
0.91
+27.00%
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Geode Capital Management LLC Buys 9,553 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Renaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Protara Therapeutics Expands Leadership Team: New CPO Receives 61,500 Equity Awards Amid Growth Push - Stock Titan
Stocks of Protara Therapeutics Inc (TARA) are poised to climb above their peers - Sete News
It would be worthwhile to take a closer look at Protara Therapeutics Inc (TARA) - uspostnews.com
Protara Therapeutics, Inc.'s (NASDAQ:TARA) institutional investors lost 14% last week but have benefitted from longer-term gains - simplywall.st
Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Sold by LPL Financial LLC - Defense World
The Potential Rise in the Price of Protara Therapeutics Inc (TARA) following insiders activity - knoxdaily.com
Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial - streetwisereports.com
Protara Therapeutics Inc Inc. (TARA) Price Performance: A Technical Analysis Perspective - investchronicle.com
Balance Sheet Breakdown: Protara Therapeutics Inc (TARA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Protara Therapeutics (NASDAQ:TARA) Given “Buy” Rating at HC Wainwright - Defense World
Protara Therapeutics stock drops following interim trial results By Investing.com - Investing.com Nigeria
Protara Therapeutics stock drops following interim trial results - Investing.com Australia
Protara Therapeutics Inc (NASDAQ: TARA)’s Potential for Significant Price Increase in the Near Future - Marketing Sentinel
Protara Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Protara Therapeutics Announces Positive Interim Results Demonstr - GuruFocus
Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC - Nasdaq
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - The Manila Times
Protara Therapeutics Reports Promising Phase 2 Results for TARA-002 in Non-Muscle Invasive Bladder Cancer - Nasdaq
3 Stocks To Watch For When Tariffs Subside - The Globe and Mail
Mountain Province Diamonds Announces Mailing of Meeting Materials For Annual and Special Meeting of Shareholders to Approve Additional Working Capital Facility - The Globe and Mail
Protara Therapeutics (TARA) to Release Quarterly Earnings on Thursday - Defense World
Protara Therapeutics Inc (TARA) gets rating Initiated from Scotiabank - knoxdaily.com
OTCQX Best 50 Virtual Investor Conference Agenda Announced for April 24th - The Globe and Mail
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 - The Manila Times
Protara Therapeutics to Host Conference Call on Phase 2 ADVANCED-2 Trial Data for TARA-002 in Non-Muscle Invasive Bladder Cancer - Nasdaq
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Protara's Bladder Cancer Drug TARA-002 Phase 2 Trial: 12-Month Efficacy Data Reveal Coming at Major Conference - Stock Titan
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
No-Brainer Buy Alert: 1 Artificial Intelligence (AI) Stock With Massive Long-Term Potential - The Globe and Mail
Examining TARA’s book value per share for the latest quarter - uspostnews.com
Philip Morris (PM) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $22.50 - Defense World
Protara Therapeutics (NASDAQ:TARA) Earns Sector Outperform Rating from Analysts at Scotiabank - Defense World
Where Will Nvidia Stock Be in 5 Years? - The Globe and Mail
Protara Therapeutics Announces Appointment of Leonardo Viana Nic - GuruFocus
Scotiabank Initiates Coverage of Protara Therapeutics (TARA) with Sector Outperform Recommendation - Nasdaq
Scotiabank Initiates Protara Therapeutics at Sector Outperform With $12 Price Target - marketscreener.com
Protara Therapeutics (TARA) Rated Outperform with $12 Target by Scotiabank | TARA Stock News - GuruFocus
Protara Therapeutics (TARA) Names Leonardo Viana Nicacio as New Chief Medical Officer | TARA Stock News - GuruFocus
Protara Therapeutics Names Leonardo Viana Nicacio CMO - marketscreener.com
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer - The Manila Times
Strategic Leadership Boost: Protara Gains 20-Year Oncology Expert as CMO Ahead of Key Trial Data - Stock Titan
Could Protara's ADVANCED-2 Trial Data Trigger A Stock Rally? - RTTNews
Protara Therapeutics to Present Interim Analysis from the Phase - GuruFocus
Commonwealth Equity Services LLC Has $195,000 Stock Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara to present bladder cancer trial data at AUA meeting By Investing.com - Investing.com Canada
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade - MSN
Protara to present bladder cancer trial data at AUA meeting - Investing.com Australia
Protara Therapeutics to Present Interim Analysis from the - GlobeNewswire
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting - TradingView
5.24%
자본화:
|
볼륨(24시간):